• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Empaglifozin reduces death in heart failure patients with preserved ejection fraction

byBoaz WongandHarsh Shah
November 2, 2021
in Cardiology, Chronic Disease, Endocrinology, Nephrology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Empaglifozin treatment was shown to have reduced rates of cardiovascular death or hospitalization in patients with heart failure and preserved ejection fraction.

2. Both treatment groups had a similar percentage of patients discontinuing the therapy.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs shown to reduce the progression of heart failure in patients with reduced ejection fraction; however, this effect is unknown in heart failure patients with preserved ejection fraction. In this randomized control trial, patients with chronic heart failure and left ventricular ejection fraction of more than 40% were randomized to either receive 10mg of empagliflozin once daily or placebo treatment. The primary outcome was the incidence of cardiovascular death or hospitalization solely due to heart failure events. The study found that empagliflozin treatment was able to lower the risk of hospitalization compared to the placebo group, but the effect was not observed for cardiovascular deaths. This effect was found irrespective of patient diabetes status. Rates of serious adverse events were similar between the two groups. The study was limited by a high rate of discontinuation amongst both groups for reasons other than death. Together, this study establishes the basis of empagliflozin use in patients with heart failure and preserved ejection fraction to prevent adverse cardiovascular outcomes.

Click to read the study in NEJM

Relevant Reading: SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials

RELATED REPORTS

Oral semaglutide reduces cardiovascular event rates in high-risk patients

Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes

Diabetic polyneuropathy observed to have dynamic changes overtime

In-Depth [randomized controlled trial]: In this randomized controlled trial, 5988 patients were enrolled from 622 centers in 23 countries. Patients with a New York Heart Association functional class II-IV chronic heart failure and a left ventricular ejection fraction greater than 40% were included in the study. Patients were excluded if they had a disorder that would change their clinical course. The patients were randomized in a 1:1 ratio to either receive empagliflozin (10mg) or placebo treatment, respectively. Groups were also stratified by geographic region, diabetes status, estimated glomerular filtration rate (eGFR), and left ventricular ejection fraction greater than 50%. The primary outcome was the time between first treatment and incidence of cardiovascular-related hospitalization or death due to heart failure. In a median of 26.2 months to first event, 415 (13.8%) patients receiving empagliflozin experience the primary outcome compared to 511 (17.1%) patients in the placebo group 9hazard ratio [HR], 0.79; 95%confidence interval [CI], 0.69 to 0.90; P<0.001). When the primary outcomes were separated, patients receiving empagliflozin continued to demonstrate a lower rate of hospitalizations than the placebo group (HR, 0.71; 95%CI, 0.60 to 0.83). Conversely, the effect was not significant for the incidence of heart failure-related deaths (HR, 0.91; 95%CI, 0.76 to 1.09). These effects were also observed when patients were stratified for diabetes status. Altogether, the study supports the use of empagliflozin in heart failure patients with a preserved ejection fraction.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cardiovascular eventscardiovascular mortalitydiabeteseGFRempaglifozinheart failureHFpEF (heart failure with preserved ejection fractionSGLT-2 inhibitors
Previous Post

Multimodal physical interventions may lower concussion symptom scores

Next Post

COVID-19-related hospital policies not associated with delays in urgent open and closed fracture surgeries compared to pre-pandemic

RelatedReports

Mediterranean diet linked to reduced diabetes risk in high risk cardiovascular patients
Cardiology

Oral semaglutide reduces cardiovascular event rates in high-risk patients

June 5, 2025
Increased number of daily steps linked with decreased mortality in older women
Chronic Disease

Semaglutide improves walking ability in patients with peripheral artery disease and type 2 diabetes

May 29, 2025
Chronic Disease

Diabetic polyneuropathy observed to have dynamic changes overtime

May 21, 2025
Food environment associated with gestational diabetes
Pharma

Eli Lilly Takes Legal Action Against Telehealth Startups

May 15, 2025
Next Post
Quick Take: Intravenous patient-controlled analgesia versus thoracic epidural analgesia after open liver surgery

COVID-19-related hospital policies not associated with delays in urgent open and closed fracture surgeries compared to pre-pandemic

Rivaroxaban likely reduces risk of recurrent stroke in specific subgroup of patients with embolic stroke of undetermined source

Systematic screening for atrial fibrillation may reduce morbidity and mortality in older patients

Poverty, preterm birth demonstrate additive effect on cognition

Phototherapy not associated with increased risk of childhood cancer

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Dapagliflozin may improve outcomes in patients with metabolic dysfunction-associated steatohepatitis
  • Early induction of labour reduces shoulder dystocia rates in large for gestational age fetuses
  • Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.